LB Pharmaceuticals Management
Management criteria checks 0/4
LB Pharmaceuticals' CEO is Heather Turner, appointed in Nov 2024, has a tenure of 1.5 years. total yearly compensation is $11.88M, comprised of 4.8% salary and 95.2% bonuses, including company stock and options. directly owns 0.24% of the company’s shares, worth $1.94M. The average tenure of the management team and the board of directors is 0.5 years and 2.8 years respectively.
Key information
Heather Turner
Chief executive officer
US$11.9m
Total compensation
| CEO salary percentage | 4.79% |
| CEO tenure | 1.5yrs |
| CEO ownership | 0.2% |
| Management average tenure | less than a year |
| Board average tenure | 2.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$39m |
| Dec 31 2025 | US$12m | US$569k | -US$25m |
| Sep 30 2025 | n/a | n/a | -US$19m |
| Jun 30 2025 | n/a | n/a | -US$29m |
| Mar 31 2025 | n/a | n/a | -US$52m |
| Dec 31 2024 | US$5m | US$69k | -US$63m |
Compensation vs Market: Heather's total compensation ($USD11.88M) is above average for companies of similar size in the US market ($USD3.70M).
Compensation vs Earnings: Heather's compensation has increased whilst the company is unprofitable.
CEO
Heather Turner (52 yo)
Ms. Heather D. Turner, J. D., Esq., is Chief Executive Officer and Director of LB Pharmaceuticals Inc from November 2024. She has been Independent Chairman of Avalyn Pharma Inc. since October 2024. She was...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.5yrs | US$11.88m | 0.24% $ 1.9m | |
| Co-founder | no data | US$564.88k | 0.21% $ 1.7m | |
| Chief Operating & Business Officer | less than a year | US$3.85m | 0.029% $ 236.3k | |
| Chief Medical Officer | 5.7yrs | US$2.38m | 0.013% $ 100.8k | |
| Senior Vice President of Finance | 10.2yrs | no data | 0.036% $ 288.0k | |
| General Counsel | less than a year | no data | no data | |
| Senior VP of People & Culture | less than a year | no data | no data | |
| Senior Vice President of Technical Operations | 1.3yrs | no data | no data | |
| Senior Vice President of Regulatory Affairs | less than a year | no data | no data | |
| Senior Vice President of Corporate Affairs | less than a year | no data | no data | |
| Chief Commercial Officer | less than a year | no data | no data |
Experienced Management: LBRX's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.5yrs | US$11.88m | 0.24% $ 1.9m | |
| Co-founder | 10.7yrs | US$564.88k | 0.21% $ 1.7m | |
| Independent Director | 6.8yrs | US$365.00k | 0.0083% $ 66.5k | |
| Chairman of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.8yrs | US$246.51k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | less than a year | US$246.82k | no data | |
| Independent Chairman of the Board | 2.3yrs | US$386.98k | 0.040% $ 323.4k | |
| Member of Scientific Advisory Board | 10yrs | no data | no data | |
| Independent Director | 2.8yrs | US$248.04k | no data | |
| Independent Director | less than a year | US$252.91k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
Experienced Board: LBRX's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/25 23:18 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
LB Pharmaceuticals Inc is covered by 6 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Adam Vogel | Craig-Hallum Capital Group LLC |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Marc Goodman | Leerink Partners LLC |